194 related articles for article (PubMed ID: 36221229)
21. Antibiotic use and development of nonalcoholic fatty liver disease: A population-based case-control study.
Ebrahimi F; Simon TG; Hagström H; Sun J; Bergman D; Forss A; Roelstraete B; Engstrand L; Ludvigsson JF
Liver Int; 2023 Oct; 43(10):2186-2197. PubMed ID: 37387502
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
[TBL] [Abstract][Full Text] [Related]
23. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
24. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
[TBL] [Abstract][Full Text] [Related]
25. Association of nonalcoholic fatty liver disease and liver cancer.
Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
[TBL] [Abstract][Full Text] [Related]
26. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus.
Chen N; Zhou J; Wang K; Li X; Li Z
BMJ Open Diabetes Res Care; 2023 Feb; 11(1):. PubMed ID: 36792168
[TBL] [Abstract][Full Text] [Related]
27. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
[TBL] [Abstract][Full Text] [Related]
28. Nonalcoholic fatty liver disease and risk of incident young-onset hypertension: Effect modification by sex.
Kim Y; Chang Y; Ryu S; Park S; Cho Y; Sohn W; Kang J; Wild SH; Byrne CD
Nutr Metab Cardiovasc Dis; 2023 Aug; 33(8):1608-1616. PubMed ID: 37357078
[TBL] [Abstract][Full Text] [Related]
29. The sulfur microbial diet and risk of nonalcoholic fatty liver disease: a prospective gene-diet study from the UK Biobank.
Liu Z; Huang H; Ruan J; Wang Z; Xu C
Am J Clin Nutr; 2024 Feb; 119(2):417-424. PubMed ID: 38000660
[TBL] [Abstract][Full Text] [Related]
30. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study.
Allen AM; Therneau TM; Larson JJ; Coward A; Somers VK; Kamath PS
Hepatology; 2018 May; 67(5):1726-1736. PubMed ID: 28941364
[TBL] [Abstract][Full Text] [Related]
31. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis.
Mantovani A; Dauriz M; Byrne CD; Lonardo A; Zoppini G; Bonora E; Targher G
Metabolism; 2018 Oct; 87():1-12. PubMed ID: 29935236
[TBL] [Abstract][Full Text] [Related]
32. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
Yuan X; Wang X; Wu S; Chen S; Wang Y; Wang J; Lu Y; Sun Y; Fu Q; Wang L
Hepatobiliary Surg Nutr; 2023 Oct; 12(5):671-681. PubMed ID: 37886198
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Thomas JA; Kendall BJ; Dalais C; Macdonald GA; Thrift AP
Eur J Cancer; 2022 Sep; 173():250-262. PubMed ID: 35944373
[TBL] [Abstract][Full Text] [Related]
34. Higher ultra-processed food intake is associated with adverse liver outcomes: a prospective cohort study of UK Biobank participants.
Zhao L; Clay-Gilmour A; Zhang J; Zhang X; Steck SE
Am J Clin Nutr; 2024 Jan; 119(1):49-57. PubMed ID: 37871746
[TBL] [Abstract][Full Text] [Related]
35. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study.
Wu S; Yuan C; Yang Z; Liu S; Zhang Q; Zhang S; Zhu S
BMC Med; 2022 Aug; 20(1):262. PubMed ID: 35989356
[TBL] [Abstract][Full Text] [Related]
36. Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.
Sung KC; Yoo TK; Lee MY; Byrne CD; Zheng MH; Targher G
Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):482-491. PubMed ID: 36727522
[TBL] [Abstract][Full Text] [Related]
37. Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation.
Cai X; Zheng S; Liu Y; Zhang Y; Lu J; Huang Y
Liver Int; 2020 Jul; 40(7):1594-1600. PubMed ID: 32279432
[TBL] [Abstract][Full Text] [Related]
38. Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?
Mitsala A; Tsalikidis C; Romanidis K; Pitiakoudis M
Curr Oncol; 2022 Jun; 29(7):4478-4510. PubMed ID: 35877216
[TBL] [Abstract][Full Text] [Related]
39. Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).
Cuthbertson DJ; Koskinen J; Brown E; Magnussen CG; Hutri-Kähönen N; Sabin M; Tossavainen P; Jokinen E; Laitinen T; Viikari J; Raitakari OT; Juonala M
Ann Med; 2021 Dec; 53(1):1256-1264. PubMed ID: 34309471
[TBL] [Abstract][Full Text] [Related]
40. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study.
Lin XF; Shi KQ; You J; Liu WY; Luo YW; Wu FL; Chen YP; Wong DK; Yuen MF; Zheng MH
Mol Biol Rep; 2014 May; 41(5):2989-97. PubMed ID: 24449368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
